Drug intelligence / Profile preview

durvalumab + savolitinib

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

Durvalumab + savolitinib is a combination therapy consisting of durvalumab, a PD-L1 inhibitor, and savolitinib, a potent and selective MET inhibitor. This combination has been investigated primarily for the treatment of metastatic papillary renal cell carcinoma (PRCC), particularly in patients with MET-driven tumors. The combination works by targeting both the MET pathway (savolitinib) and immune checkpoint inhibition (durvalumab) to potentially enhance anti-tumor activity.

Brand names: Orpathys + ImfinziVoressa + Imfinzi
Other names: Volitinib + Imfinzi

Targets

CD274 (Programmed cell death protein 1 ligand 1)MET (Mesenchymal-epithelial transition factor receptor)

Beyond the preview

Go deeper on durvalumab + savolitinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on durvalumab + savolitinib.

Explore the full profile